Business
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for f
About this update from Volitionrx Limited
[{"type":"text","content":"Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection","length":82,"tagName":"p"},{"type":"text","content":"HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.","length":622,"tagName":"p"},{"type":"text","content":"Frédéric Wuilque, VP-Global Products, Volition commented :","length":68,"tagName":"p"},{"type":"text","content":""Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years.","length":243,"tagName":"p"},{"type":"text","content":""Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.","length":252,"tagName":"p"},{"type":"text","content":""We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms."","length":213,"tagName":"p"},{"type":"text","content":"The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:","length":74,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Large Population: There are approximately 73.8 million pet cats in the United States alone3.","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"High Risk: It is estimated that approximately 1 in 5 cats will develop cancer in their lifetime4. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.","length":194,"tagName":"p"}]},{"val":[{"ty...